TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31030961
Drug: α‐bungarotoxin (α7
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐bungarotoxin (α7 nicotinic acetylcholine receptor antagonist)
Study: 25795717
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusions for counts <10×10(9)/L
Study: 25795717
Drug: Days with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days with platelet count <10×10(9)/L
Study: 23851346
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg, 1‐h IV infusion) with cyclosporine (5 mg/kg, 2‐h infusion)
Study: 23851346
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg, 1‐h IV infusion) without cyclosporine (control)
Study: 19207890
Drug: Mechanical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical periodontal treatment with local application of minocycline (APT)
Study: 8256504
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of Recombivax HB given at 3 or 4 years
Study: 11164146
Drug: Terazosin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin treatment
Study: 18663165
Drug: Colesevelam hydrochloride,
Normalized name: Colesevelam Hydrochloride, 625 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam hydrochloride, 3.75 g/d
Study: 18852398
Drug: Colesevelam hydrochloride,
Normalized name: Colesevelam Hydrochloride, 625 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam hydrochloride, 3.75 g/d (metformin monotherapy cohort)
Study: 18852398
Drug: Colesevelam hydrochloride,
Normalized name: Colesevelam Hydrochloride, 625 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam hydrochloride, 3.75 g/d (combination therapy cohort)
Study: 12064336
Drug: Eggshell powder-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eggshell powder-enriched supplement (group A; n=24)
Study: 12064336
Drug: Purified CaCO3-enriched
Normalized name: Purified oxgall
DrugBank: Ox bile extract (DB14016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified CaCO3-enriched supplement (group B; n=22)
Study: 10598691
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of 2% dorzolamide (three times daily) and 0.5% timolol (twice daily)
Study: 8707080
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1 g twice daily
Study: 8707080
Drug: Sulphasalazine 1
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphasalazine 1 g twice daily
Study: 1684492
Drug: Bunazosin hydrochloride
Normalized name: bunazosin hydrochloride
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin hydrochloride 0.025%, 0.05%, 0.1%, and 0.2% (topical administration)
Study: 1684492
Drug: Bunazosin hydrochloride
Normalized name: bunazosin hydrochloride
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin hydrochloride 0.1% (multiple doses)
Study: 25197740
Drug: Mechanical cleaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical cleaning with interdental brushes combined with cetylpyridinium chloride (0.3% CPC) gel
Study: 19299272
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) with anti-inflammatory agent (60 mg oral acemetacine twice daily for 10 days)
Study: 19299272
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (Ca-nadroparin 190 IUAxa/kg in a single dose)
Study: 17516022
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg once-yearly for 2, 3 or 5 years
Study: 17516022
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg once-yearly
Study: 15468607
Drug: Trazodone (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (50-100 mg)
Study: 15468607
Drug: Zaleplon (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon (10-20 mg)
Study: 28167747
Drug: Hospital-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based treatment as usual
Study: 29911601
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone (OXY)
Study: 29911601
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (IVM) followed by codeine
Study: 21140258
Drug: Sublingual Salvinorin
Normalized name: Salvinorin A
DrugBank: Salvinorin A (DB12327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Salvinorin A (SA) up to 4 mg
Study: 18245546
Drug: OGX-011 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OGX-011 at 640 mg
Study: 18245546
Drug: Docetaxel (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (30 mg/m2 weekly for 5 of 6 weeks or 75 mg/m2 every 3 weeks)
Study: 16989201
Drug: Dry air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry air radon baths (DARB) with radon concentration 40 nCi/l
Study: 16989201
Drug: Dry air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry air radon baths (DARB) with radon concentration 20 nCi/l
Study: 12975739
Drug: Rapacuronium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 1.5 mg/kg with neostigmine
Study: 12975739
Drug: Rapacuronium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 1.5 mg/kg without neostigmine
Study: 6594473
Drug: 2 million
Normalized name: Carticel 12 million cells/vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 million units aqueous penicillin G intravenously every four hours for a total of 12 doses (two days) postoperatively
Study: 6594473
Drug: Placebo intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenously every four hours for a total of 12 doses (two days) postoperatively
Study: 27879604
Drug: Negative-pressure wound
Normalized name: Microcyn Negative-Pressure Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure wound therapy for 5 days after primary closure
Study: 19032906
Drug: Krypton yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton yellow laser photocoagulation around the hole margin with oral placebo (vitamin B1)
Study: 19032906
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (vitamin B1) only
Study: 12523894
Drug: Chronic suppressive
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic suppressive oral acyclovir
Study: 12523894
Drug: Chronic suppressive
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic suppressive oral acyclovir targeting patients with a history of stromal keratitis
Study: 6340249
Drug: O‐(beta‐Hydroxyethyl)‐rutoside administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: O‐(beta‐Hydroxyethyl)‐rutoside administered intravenously daily before each radiation
Study: 17592099
Drug: Pravastatin, vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin, vitamin E, and homocysteine lowering therapy
Study: 20067456
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (150 mg twice daily)
Study: 9647605
Drug: Cysteinyl leukotriene
Normalized name: bis(cysteinyl maleimide) PEG 20000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteinyl leukotriene receptor antagonist (zafirlukast)
Study: 7663802
Drug: 5-lipoxygenase inhibitor
Normalized name: 5-lipoxygenase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-lipoxygenase inhibitor (zileuton)
Study: 9647605
Drug: Antileukotriene agents
Normalized name: ANTIASTHMA,ANTILEUKOTRIENES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antileukotriene agents (general)
Study: 2542682
Drug: naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone (0.8 mg i.v.)
Study: 1146722
Drug: Tocopherol-stripped safflower
Normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocopherol-stripped safflower oil containing 88 g of polyunsaturated fatty acids and 2.3 mg of tocopherols.
Study: 30418340
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of modified Sinaki exercises and Nordic Walking
Study: 23342765
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drugs only)
Study: 26404895
Drug: Daily exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exercise programme
Study: 22310310
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide synthase (NOS) inhibition via intra-arterial infusion of N(G)-monomethyl-L-arginine (L-NMMA)
Study: 20027346
Drug: IFN inductor
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN inductor anaferon (pediatric formulation)
Study: 770083
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin per day
Study: 9017526
Drug: Sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release methylphenidate (MSR) 20-40 mg/day
Study: 9017526
Drug: Sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release methylphenidate (MSR)
Study: 8506913
Drug: Pentoxifylline 2000
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline 2000 mg
Study: 2969740
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg doxazosin
Study: 2951051
Drug: Doxazosin (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (2, 4, and 8 mg)
Study: 23994382
Drug: Pegasys (PegIFNα)
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegasys (PegIFNα) weekly dosing of 360 μg
Study: 23994382
Drug: Viread (tenofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viread (tenofovir disoproxil fumarate, TDF) daily dose of 300 mg
Study: 23994382
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pegasys and Viread
Study: 22743137
Drug: Early hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early hCG administration (hCG 5000 IU, IM when leading follicle diameter 16.0-16.9 mm)
Study: 22743137
Drug: Late hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late hCG administration (hCG 5000 IU, IM when leading follicle diameter 18.0-18.9 mm)
Study: 16630151
Drug: PLA(2) peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLA(2) peptide vaccine
Study: 10618542
Drug: HIV SF2
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV SF2 gp120/MF59 vaccine (50 microg)
Study: 8839901
Drug: Fadrozole 1
Normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole 1 mg twice daily
Study: 3323603
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and metoprolol (beta adrenergic antagonists)
Study: 29866385
Drug: Brief behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief behavioral treatment (BT) based on motivational interviewing and cognitive behavioral therapy
Study: 29866385
Drug: Medication-assisted treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-assisted treatment (MAT) with extended-release injectable naltrexone (XR-NTX) for alcohol use disorder or buprenorphine/naloxone (BUP/NX) for opioid use disorder
Study: 26673981
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of IVIG (n = 32)
Study: 25671931
Drug: Deferiprone (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (75 mg/kg in three divided doses orally)
Study: 25671931
Drug: Deferrioxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferrioxamine (50 mg/kg/24hrs for 5 days/week as parental infusion)
Study: 19384263
Drug: MeNZB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MeNZB vaccine (25 mug) administered with routine immunizations and a fourth dose at 10 months (n = 250)
Study: 17569575
Drug: Computer reminders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer reminders for antibiotic prescriptions
Study: 17569575
Drug: Computer reminders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer reminders for asthma/COPD prescriptions
Study: 17569575
Drug: Specific recommendations
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific recommendations (quinolones for cystitis, corticosteroids for COPD, antibiotics for acute sore throat)
Study: 9764988
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (10 mg kg(‐1).d(‐1), given in single daily doses)
Study: 9764988
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (10 mg kg(‐1).d(‐1), given in multiple daily doses)
Study: 3265347
Drug: Low-dose perioperative
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose perioperative interferon-alpha (r-HuIFN alpha), 2 megaunits daily for 1 week starting the evening before surgery
Study: 29473352
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (Baclofen 10 mg, 3 times a day for 4 weeks)
Study: 27261998
Drug: Ayurvedic herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic herbal compound preparation (Murraya koenigii, Punica granatum, Curcuma longa), administered as a decoction twice daily for 4 weeks
Study: 27261998
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered as ground powders for 4 weeks
Study: 27261998
Drug: Ayurvedic herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic herbal compound preparation
Study: 17928573
Drug: Risperidone augmentation
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone augmentation (0.25-1 mg)
Study: 8838964
Drug: Peroral amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroral amoxicillin 0.75 g 3 times daily (n = 50)
Study: 1627419
Drug: Modified radical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified radical mastectomy or partial mastectomy plus radiation therapy
Study: 6476838
Drug: Mitoxantrone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone at dosages of 2 to 4 mg/m2 with a 5‐day schedule or 6 to 12 mg/m2 with a one day schedule, repeating at 4‐week intervals
Study: 31206579
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (information about local substance use treatment services)
Study: 26945358
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer solution (LR)
Study: 19155234
Drug: DAS-driven therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS-driven therapy (group A)
Study: 17698144
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial scrub with 4% chlorhexidine
Study: 16361166
Drug: Bupivacaine (0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.75% 6 mg, diluted to 2 ml with distilled water)
Study: 12099982
Drug: Tacrolimus (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (dosage not specified)
Study: 10641952
Drug: 0.625mg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625mg of conjugated equine estrogens plus 2.5mg of medroxyprogesterone daily (Prempro)
Study: 7772614
Drug: Selective MAO-A
Normalized name: Mao cang zhu rhizome
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective MAO-A inhibitors (moclobemide, brofaromine)
Study: 2304788
Drug: Mother and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mother and child treated in separate but concurrent session
Study: 30981585
Drug: Second generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation antipsychotics (SGAs) - haloperidol, flupentixol
Study: 30981585
Drug: First generation
Normalized name: First generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: First generation antipsychotics (FGAs) - aripiprazole, olanzapine, quetiapine
Study: 18794865
Drug: Etoposide and
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide and G-CSF
Study: 18794865
Drug: Etoposide, G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide, G-CSF and rituximab
Study: 16931805
Drug: Graphic instructions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graphic instructions for missed pill guidance
Study: 16931805
Drug: Text-only instructions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text-only instructions for missed pill guidance
Study: 9460867
Drug: Russian vaccine
Normalized name: Russian thistle pollen extract
DrugBank: Salsola kali pollen (DB10388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Russian vaccine 'Combiotech'
Study: 9460867
Drug: American vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: American vaccine 'H-B-Vax II'
Study: 9460867
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (schedule 0-1-2 months)
Study: 9460867
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (schedule 0-1-6 months)
Study: 9460867
Drug: Children receiving
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children receiving only the vaccines
Study: 8404168
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline (TE)
Study: 30776537
Drug: Previous weak
Normalized name: weakleaf bur ragweed pollen extract
DrugBank: Ambrosia confertiflora pollen (DB10872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous weak opioid therapy
Study: 25243960
Drug: Fuzhenghuayu capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzhenghuayu capsule plus propranolol
Study: 25243960
Drug: Fuzhenghuayu capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzhenghuayu capsule alone
Study: 7640497
Drug: Compound salviae
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound salviae miltiorrhizae injection
Study: 2486590
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine + 1 mg butorphanol (Group I)
Study: 2486590
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine + 2 mg butorphanol (Group II)
Study: 2486590
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine + 2 mg morphine (Group III)
Study: 25412300
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise program (EX), combining continuous steady-state and interval cycling at various intensities, in combination with unsupervised moderate intensity aerobic activity and conventional diabetic management
Study: 23470235
Drug: Sertaconazole 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertaconazole 2% cream applied twice daily for 1 month
Study: 23470235
Drug: Hydrocortisone 1%
Normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone 1% ointment applied twice daily for 1 month
Study: 21528627
Drug: Low-intensity vibration
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity vibration (LIV) at 0.27 +/- 0.11 g; 34 Hz
Study: 21528627
Drug: Low-intensity vibration
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity vibration (LIV) at 0.44 +/- 0.18 g; 34 Hz
Study: 11783255
Drug: Sini Decoction
Normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sini Decoction (SND), 25 ml daily from 3 days before operation to the third day after operation.
Study: 2551560
Drug: Dilevalol (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (25, 50, and 50 mg bolus injections at 15-minute intervals)
Study: 31693083
Drug: Stellate Ganglion
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stellate Ganglion Block (SGB) treatment
Study: 26887208
Drug: Heat-sensitive moxibustion
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-sensitive moxibustion applied to Guanyuan (GV 4) for 40 min, once daily for (7 +/- 2) days in one menstrual cycle, for 3 menstrual cycles.
Study: 16289676
Drug: Bio-adhesive 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-adhesive 0.2% chlorhexidine gel applied once during surgery
Study: 16289676
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied once during surgery